Red Light Holland's Wholly Owned Subsidiary, Filament Health, Expands Distribution of PEX010 Across Canadian and U.S. Research Institutions
Red Light Holland expanded shipments of its subsidiary Filament Health's botanical psilocybin candidate PEX010 to several North American research institutions and compassionate use programs. Recipients include the University of Calgary and UCSF for ongoing studies on alcohol use disorder and chronic pain, alongside a new Canadian academic partner.
Key figures
- Patents issued
- 76
- Patent families
- 15
- Research studies count
- more than 70
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.